Join Dr. Usmani as he recommends the steps community oncologists should take to differentiate between, and provide ideal follow-up to, MGUS and smoldering MM patients.

Join Dr. Orlowski as he explains when to use daratumumab-lenalidomide-dexamethasone versus daratumumab-bortezomib-dexamethasone in clinical practice with multiple myeloma patients.

Join Dr. Usmani as he details the lab, biopsy-specific, and imaging-specific tests the community oncologist needs to consider when establishing a multiple myeloma diagnosis.

Join Dr. Orlowski as he defines aggressive symptomatic relapse and explains which drug regimens are recommended for rapidly progressing disease.

Join Dr. Orlowski as he recommends drug regimens for treating patients with asymptomatic biochemical relapse with slow versus rapid rise in M-protein levels.

Join Dr. Stadtmauer as he explains how to define and measure minimal residual disease (MRD) in patients with multiple myeloma, as well as the clinical implications of this technique to patient care.

Join Dr. Richter as he discusses the difference between smoldering myeloma and symptomatic multiple myeloma, and emerging criteria to classify and treat the former.

Join Dr. Giralt as he explains whether or not you should wait for the development of CRAB before initiating therapy for your multiple myeloma patients.

Join Dr. Landgren as he discusses the relative value of multicolor flow cytometry in an assessment for minimal residual disease (MRD) in multiple myeloma, compared to allele-specific PCR.

Join Dr. Orlowski as he discusses how to select between carfilzomib and ixazomib as a proteosome inhibitor, especially in the relapsed or refractory setting.